NCT00842283 Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
| NCT ID | NCT00842283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Irvine |
| Condition | Dermatologic Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 85 participants |
| Start Date | 2008-11 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 85 participants in total. It began in 2008-11 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease. Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways. De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.
Eligibility Criteria
Inclusion Criteria: * 16 years of age or older. * willing to have a skin biopsy Exclusion Criteria: * under 16 years of age * unable to carry out instructions
Contact & Investigator
Kristen Kelly, MD
PRINCIPAL INVESTIGATOR
University of California, Irvine
Frequently Asked Questions
Who can join the NCT00842283 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Dermatologic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00842283 currently recruiting?
Yes, NCT00842283 is actively recruiting participants. Contact the research team at hhkim3@uci.edu for enrollment information.
Where is the NCT00842283 trial being conducted?
This trial is being conducted at Irvine, United States, Irvine, United States.
Who is sponsoring the NCT00842283 clinical trial?
NCT00842283 is sponsored by University of California, Irvine. The principal investigator is Kristen Kelly, MD at University of California, Irvine. The trial plans to enroll 85 participants.